

Ipsen's corporate agenda for 2013

Paris (France), 3 January 2013 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today its corporate agenda* for 2013:

30 January 2013:	Full year 2012 sales
27 February 2013:	Full year 2012 results
25 April 2013:	First quarter 2013 sales
31 May 2013:	General shareholders' meeting
10 June 2013:	Payment of 2012 dividend**
30 August 2013:	First half 2013 sales & results
30 October 2013:	First nine months 2013 sales

* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary

** Pending approval of the Board of directors (26th February 2013) and of the General shareholders' meeting (31st May 2013)

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport[®], endocrinology / Somatuline[®], uro-oncology / Decapeptyl[®] and hemophilia. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

For further information:

Media

Didier Véron

Vice President, Public Affairs and Corporate Communications

Tel.: +33 (0)1 58 33 51 16

Fax: +33 (0)1 58 33 50 58

E-mail: didier.veron@ipsen.com

Financial Community

Pierre Kemula

Vice President, Corporate Finance, Treasury and Financial Markets

Tel.: +33 (0)1 58 33 60 08

Fax: +33 (0)1 58 33 50 63

E-mail: pierre.kemula@ipsen.com

Stéphane Durant des Aulnois

Investor Relations Manager

Tel.: +33 (0)1 58 33 60 09

Fax: +33 (0)1 58 33 50 63

E-mail:

stephane.durant.des.aulnois@ipsen.com